FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387084311> ?p ?o ?g. }

• W4387084311 abstract "Abstract Background: Ciprofol is a novel intravenous sedative and anesthetic. Studies have shown that it features a rapid onset of action, a fast recovery time, slight inhibition of respiratory and cardiovascular functions, and a low incidence of adverse reactions. This study aims to explore the median effective dose (ED 50 ) and the 95% effective dose (ED 95 ) of ciprofol in inhibiting responses to gastroscope insertion when combining with low dose alfentanil, and to evaluate its safety, to provide a reference for the rational use of ciprofol in clinical practices. Methods : We included 25 patients aged 18-64 years of either sex who underwent gastroscopy under intravenous general anesthesia, with a Body Mass Index (BMI) 18-28 kg/m 2 , and an American Society of Anesthesiologists (ASA) grade I or II. In this study, the dose-finding strategy of ciprofol followed a modified Dixon’s up-and-down method with an initial dose of 0.30 mg/kg and an increment of 0.02 mg/kg. Ciprofol was administered after intravenous injection of 7 µg/kg of alfentanil, and 2 minutes later a gastroscope was inserted. When the insertion response of one participant was positive (including body movement, coughing, and eye opening), an escalation of 0.02 mg/kg would be given to the next participant; otherwise, a de-escalation of 0.02 mg/kg would be administered. The study was terminated when negative response and positive response alternated 8 times. A Probit model was used to calculate the ED 50 and ED 95 of ciprofol in inhibiting responses to gastroscope insertion when combined with alfentanil. Patients' recovery time, discharge time, vital signs and occurrence of adverse reactions were recorded. Results : The ED 50 of single-dose intravenous ciprofol injection with 7 µg/kg of alfentanil in inhibiting gastroscope insertion responses was 0.217 mg/kg, and the ED 95 was 0.247 mg/kg. Patients’ recovery time and discharge time were (11.04±1.49) minutes and (9.64±2.38) minutes, respectively. The overall incidence of adverse reactions was 12%. Conclusion : The ED 50 of ciprofol combined with 7 µg/kg of alfentanil in inhibiting gastroscope insertion responses was 0.217 mg/kg, and the ED 95 was 0.247 mg/kg. Ciprofol showed a low incidence of anesthesia-related adverse events. Registration : http://www.chictr.org.cn (ChiCTR2200061727)." @default.
• W4387084311 created "2023-09-28" @default.
• W4387084311 creator A5013946920 @default.
• W4387084311 creator A5029060394 @default.
• W4387084311 creator A5049516083 @default.
• W4387084311 creator A5053642441 @default.
• W4387084311 creator A5053917532 @default.
• W4387084311 creator A5082316652 @default.
• W4387084311 date "2023-09-27" @default.
• W4387084311 modified "2023-09-28" @default.
• W4387084311 title "Effective doses of ciprofol combined with alfentanil in inhibiting responses to gastroscope insertion, a prospective, single-arm, single- center clinical study" @default.
• W4387084311 doi "https://doi.org/10.21203/rs.3.rs-3293210/v1" @default.
• W4387084311 hasPublicationYear "2023" @default.
• W4387084311 type Work @default.
• W4387084311 citedByCount "0" @default.
• W4387084311 crossrefType "posted-content" @default.
• W4387084311 hasAuthorship W4387084311A5013946920 @default.
• W4387084311 hasAuthorship W4387084311A5029060394 @default.
• W4387084311 hasAuthorship W4387084311A5049516083 @default.
• W4387084311 hasAuthorship W4387084311A5053642441 @default.
• W4387084311 hasAuthorship W4387084311A5053917532 @default.
• W4387084311 hasAuthorship W4387084311A5082316652 @default.
• W4387084311 hasBestOaLocation W43870843111 @default.
• W4387084311 hasConcept C120665830 @default.
• W4387084311 hasConcept C121332964 @default.
• W4387084311 hasConcept C126322002 @default.
• W4387084311 hasConcept C141071460 @default.
• W4387084311 hasConcept C197934379 @default.
• W4387084311 hasConcept C2776277131 @default.
• W4387084311 hasConcept C2777602617 @default.
• W4387084311 hasConcept C2780073493 @default.
• W4387084311 hasConcept C2781091344 @default.
• W4387084311 hasConcept C42219234 @default.
• W4387084311 hasConcept C61511704 @default.
• W4387084311 hasConcept C71924100 @default.
• W4387084311 hasConceptScore W4387084311C120665830 @default.
• W4387084311 hasConceptScore W4387084311C121332964 @default.
• W4387084311 hasConceptScore W4387084311C126322002 @default.
• W4387084311 hasConceptScore W4387084311C141071460 @default.
• W4387084311 hasConceptScore W4387084311C197934379 @default.
• W4387084311 hasConceptScore W4387084311C2776277131 @default.
• W4387084311 hasConceptScore W4387084311C2777602617 @default.
• W4387084311 hasConceptScore W4387084311C2780073493 @default.
• W4387084311 hasConceptScore W4387084311C2781091344 @default.
• W4387084311 hasConceptScore W4387084311C42219234 @default.
• W4387084311 hasConceptScore W4387084311C61511704 @default.
• W4387084311 hasConceptScore W4387084311C71924100 @default.
• W4387084311 hasLocation W43870843111 @default.
• W4387084311 hasOpenAccess W4387084311 @default.
• W4387084311 hasPrimaryLocation W43870843111 @default.
• W4387084311 hasRelatedWork W1980498815 @default.
• W4387084311 hasRelatedWork W2016117206 @default.
• W4387084311 hasRelatedWork W2030561507 @default.
• W4387084311 hasRelatedWork W2077693656 @default.
• W4387084311 hasRelatedWork W2107270900 @default.
• W4387084311 hasRelatedWork W2134904931 @default.
• W4387084311 hasRelatedWork W2167723635 @default.
• W4387084311 hasRelatedWork W3080275388 @default.
• W4387084311 hasRelatedWork W4240815131 @default.
• W4387084311 hasRelatedWork W4292059823 @default.
• W4387084311 isParatext "false" @default.
• W4387084311 isRetracted "false" @default.
• W4387084311 workType "article" @default.